<bill session="116" type="s" number="4253" updated="2023-01-11T13:45:38Z">
  <state datetime="2020-07-21">REFERRED</state>
  <status>
    <introduced datetime="2020-07-21"/>
  </status>
  <introduced datetime="2020-07-21"/>
  <titles>
    <title type="display">Second Look at Drug Patents Act of 2020</title>
    <title type="short" as="introduced">Second Look at Drug Patents Act of 2020</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the listing of patents in the Orange Book.</title>
  </titles>
  <sponsor bioguide_id="M001111"/>
  <cosponsors>
    <cosponsor bioguide_id="C001056" joined="2020-07-21"/>
  </cosponsors>
  <actions>
    <action datetime="2020-07-21">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2020-07-21" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="s" number="1617" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Government information and archives"/>
    <term name="Intellectual property"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2021-08-07T23:33:19Z" status="Introduced in Senate">Second Look at Drug Patents Act of 2020

This bill imposes additional patent reporting requirements on the manufacturers of certain drugs approved by the Federal Drug Administration.</summary>
</bill>
